Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast: Complete Statistical AnalysisIndependent statistical analysis of Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LapBand Adjustment to Improve Early Weight Loss: Complete Statistical AnalysisIndependent statistical analysis of LapBand Adjustment to Improve Early Weight Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01060592).
- LAPISIndependent statistical analysis of Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer:…
- LAPTOPIndependent statistical analysis of The Late Presenter Treatment Optimisation Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03696160).
- LARDIndependent statistical analysis of Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756730).
- Laryngeal Mask Supreme During Laparoscopic Gynecologic Surgery: Complete Statistical AnalysisIndependent statistical analysis of Laryngeal Mask Supreme During Laparoscopic Gynecologic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02125838).
- Laser Treatment for Vulvar Lichen Sclerosus: Complete Statistical AnalysisIndependent statistical analysis of Laser Treatment for Vulvar Lichen Sclerosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04134494).
- LaserFissureIndependent statistical analysis of Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02357979).
- LASORIndependent statistical analysis of Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: Complete Statistical AnalysisIndependent statistical analysis of Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures: Complete Statistical AnalysisIndependent statistical analysis of Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00610701).
- Latino-SMARTIndependent statistical analysis of An Adaptive Intervention for Depression Among Latinos Living With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03668379).
- Laxative Effectiveness of a Phytotherapeutic Tea: Complete Statistical AnalysisIndependent statistical analysis of Laxative Effectiveness of a Phytotherapeutic Tea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00872430).
- LCCC1407Independent statistical analysis of Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02276560).
- LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- LCSDecToolIndependent statistical analysis of Incorporating Veterans' Preferences Into Lung Cancer Screening Decisions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02899754).
- LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction: Complete Statistical AnalysisIndependent statistical analysis of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LEAD-2Independent statistical analysis of To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together:…
- LEADER 75Independent statistical analysis of Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- LEAPIndependent statistical analysis of AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05089708).
- LEAPIndependent statistical analysis of Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- LEAP-001Independent statistical analysis of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LEAP-OnIndependent statistical analysis of Persistence of Oral Tolerance to Peanut: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01366846).
- LEAP2Independent statistical analysis of Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LEAPSIndependent statistical analysis of Locomotor Experience Applied Post Stroke Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00243919).
- Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval,…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC: Complete Statistical AnalysisIndependent statistical analysis of LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02494921).
- Leflunomide 20 mg Tablets, Non-Fasting: Complete Statistical AnalysisIndependent statistical analysis of Leflunomide 20 mg Tablets, Non-Fasting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00834405).
- Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation: Complete Statistical AnalysisIndependent statistical analysis of Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Left Lateral Position Versus Supine Position in Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of Left Lateral Position Versus Supine Position in Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06664762).
- Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168): Complete Statistical AnalysisIndependent statistical analysis of Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00738972).
- LEFTBASHIndependent statistical analysis of Left Bundle Area Versus Selective His Bundle Pacing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04093414).
- Lemborexant Shift Work Treatment Study: Complete Statistical AnalysisIndependent statistical analysis of Lemborexant Shift Work Treatment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05344443).
- LEMTRADA-ITPIndependent statistical analysis of Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00267059).
- Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L: primary…
- Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00759603).
- Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…